How to buy Pfizer (PFE) shares in the UK

Learn how to easily invest in Pfizer shares.

Pfizer Inc
NYSE: PFE - USD
DRUG MANUFACTURERS-GENERAL
$43.89
- $0.58 ( - 1.30%)

Global stock markets soared in response to the news that American pharmaceuticals company Pfizer (PFE) has developed a vaccine, tested on 43,500 people, which it claims is 90% effective.

On the day of the announcement, Pfizer's share price rose 15%, before falling back and closing 7% up on the previous day. Other industries reacted positively to the news, with global economic hopes seemingly pinned on the vaccine.

How to buy shares in Pfizer

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: PFE in this case.
  5. Research Pfizer shares. The platform should provide the latest information available.
  6. Buy your Pfizer shares. It's that simple.
The whole process can take as little as 15 minutes.

How has coronavirus impacted Pfizer's share price?

Since the stock market crash that started in February 2020, Pfizer's share price has had significant positive movement.

Its last market close was $43.89, which is 22.78% up on its pre-crash value of $33.89 (accounting for the 17 November 2020 split) and 65.94% up on the lowest point reached during the March 2020 crash when the shares fell as low as $26.45 (accounting for the 17 November 2020 split).

If you had bought $1,000 worth of Pfizer shares at the start of February 2020, those shares would have been worth $759.55 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,233.31.

Pfizer share price (NYSE:PFE)

Use our graph to track the performance of PFE stocks over time.

Pfizer shares at a glance

Information last updated 2021-09-17.
Open$44.17
High$44.46
Low$43.31
Close$43.89
Previous close$44.47
Change$-0.58
Change %-1.3043%
Volume51,510,530
Information last updated 2021-09-17.
52-week range$31.7629 - $51.86
50-day moving average$46.5337
200-day moving average$40.4119
Wall St. target price$46.03
PE ratio18.7404
Dividend yield$1.54 (3.46%)
Earnings per share (TTM)$2.342
Promoted
eToro Free Stocks

Invest in Pfizer shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes
Capital at risk

Fees for buying 20x Pfizer shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
Freetrade logo £0 No minimum £2.88
£642.97 total
Capital at risk
eToro Free Stocks logo £0 $50 £3.20
£643.29 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £1.13
£641.22 total
Capital at risk
Stake logo £0 £50 £3.26
£643.35 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £18.41
£658.50 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £17.65
£657.74 total
Capital at risk
Fineco logo £0 No minimum £6.40
£646.49 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £17.56
£657.65 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Pfizer stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Pfizer price performance over time

Historical closes compared with the last close of $43.89

1 week (2021-09-13) -1.55%
1 month (2021-08-20) -9.91%
3 months (2021-06-18) 13.09%
6 months (2021-03-19) 23.53%
1 year (2020-09-18) 26.29%
2 years (2019-09-20) 26.08%
3 years (2018-09-20) 5.74%
5 years (2016-09-20) 36.82%

Is Pfizer under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Pfizer shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Pfizer's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.

PEG ratio

Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9255. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Pfizer's PEG ratio in relation to those of similar companies.

EBITDA

Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $20.1 billion (£14.7 billion).

The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

Financials

Revenue TTM $55.5 billion
Operating margin TTM 27.32%
Gross profit TTM $33.3 billion
Return on assets TTM 5.45%
Return on equity TTM 18.35%
Profit margin 23.8%
Book value $12.51
Market capitalisation $246.1 billion

TTM: trailing 12 months

How to short and sell Pfizer shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "PFE.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 58.7 million Pfizer shares held short by investors – that's known as the "short interest". This figure is 7.7% up from 54.5 million last month.

There are a few different ways that this level of interest in shorting Pfizer shares can be evaluated.

Short interest ratio (SIR)

Pfizer's "short interest ratio" (SIR) is the quantity of Pfizer shares currently shorted divided by the average quantity of Pfizer shares traded daily (recently around 45.8 million). Pfizer's SIR currently stands at 1.28. In other words for every 100,000 Pfizer shares traded daily on the market, roughly 1280 shares are currently held short.

To gain some more context, you can compare Pfizer's short interest ratio against those of similar companies.

However Pfizer's short interest can also be evaluated against the total number of Pfizer shares, or, against the total number of tradable Pfizer shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pfizer's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Pfizer shares in existence, roughly 10 shares are currently held short) or 0.0105% of the tradable shares (for every 100,000 tradable Pfizer shares, roughly 11 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pfizer.

Find out more about how you can short Pfizer stock.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.

Total ESG risk score

Pfizer's total ESG risk: 33.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 01/01/2019) is pretty weak – landing it in it in the 60th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare Pfizer's total ESG risk score against those of similar companies.

Environmental score

Pfizer's environmental score: 7/100

Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

Pfizer's social score: 18.47/100

Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

Pfizer's governance score: 13.68/100

Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

Pfizer's controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

Pfizer Inc was last rated for ESG on: 2019-01-01.

Total ESG score 33.15
Total ESG percentile 60
Environmental score 7
Environmental score percentile 6
Social score 18.47
Social score percentile 6
Governance score 13.68
Governance score percentile 6
Level of controversy 3

Pfizer share dividends

3.5%

Dividend yield: 3.46% of stock value

3.5%

Forward annual dividend yield: 3.51% of stock value

48.7%

Dividend payout ratio: 48.73% of net profits

Pfizer has recently paid out dividends equivalent to 3.46% of its share value annually.

Pfizer has paid out, on average, around 48.73% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.51% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 3.51% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.54 per share.

While Pfizer's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.

Pfizer's most recent dividend payout was on 7 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 29 July 2021 (the "ex-dividend date").

Pfizer's dividend yield is perhaps best considered in relation to those of similar companies.

Have Pfizer's shares ever split?

Pfizer's shares were split on a 1054:1000 basis on 17 November 2020. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer shares – just the quantity. However, indirectly, the new 5.1% lower share price could have impacted the market appetite for Pfizer shares which in turn could have impacted Pfizer's share price.

Share price volatility

Over the last 12 months, Pfizer's shares have ranged in value from as little as $31.7629 up to $51.86. A popular way to gauge a stock's volatility is its "beta".

PFE.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.679. This would suggest that Pfizer's shares are less volatile than average (for this exchange).

To put Pfizer's beta into context you can compare it against those of similar companies.

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Pfizer in the news

There are no recent company news

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site